115 related articles for article (PubMed ID: 36043370)
1. Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy.
Ma B; Zhao L; Zhang Y; Zhang F; Gao Q
Immunotherapy; 2022 Oct; 14(15):1205-1209. PubMed ID: 36043370
[No Abstract] [Full Text] [Related]
2. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
3. Pseudoprogression: an indicator for cure in combined immunotherapy?
Zhao L; Yang Y; Li W; Li T; Han L; Lin H; Gao Q
Immunotherapy; 2019 Sep; 11(13):1087-1093. PubMed ID: 31361166
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
5. Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with
Li S; Zhang J; Du W; Ren X; Zhang X
Gland Surg; 2022 Sep; 11(9):1562-1567. PubMed ID: 36221285
[TBL] [Abstract][Full Text] [Related]
6. Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.
Lin YC; Wen KC; Sung PL; Chou YT; Liew PL; Chen LY; Huang RL; Lai HC; Chang LT
J Ovarian Res; 2020 Dec; 13(1):143. PubMed ID: 33292376
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis.
Yang Z; Zhang G; Sun Q; Liu M; Shao J; Jiao S
Front Oncol; 2020; 10():611810. PubMed ID: 33604293
[TBL] [Abstract][Full Text] [Related]
10. Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience.
Yilmaz M
J Oncol Pharm Pract; 2021 Jul; 27(5):1106-1111. PubMed ID: 32799776
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
[TBL] [Abstract][Full Text] [Related]
12. A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report.
Luo X; Sun Y; Li J; Jiang Q; Yuan L; Li T; Chen M; Yao L
Front Immunol; 2022; 13():951422. PubMed ID: 36275748
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
14. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
15. Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report.
Sun S; Sun W; Xiang Q; Yang C; Chen M; Mei Z; Yang H; Zeng Z; Cao H; Tian Y; Zhang G; Qiu H
Anticancer Drugs; 2022 Jan; 33(1):e756-e759. PubMed ID: 34338238
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer.
Muaibati M; Abuduyilimu A; Zhang T; Dai Y; Li R; Huang F; Li K; Tong Q; Huang X; Zhuang L
Expert Rev Mol Med; 2023 Jan; 25():e6. PubMed ID: 36691778
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
18. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors.
Asano Y; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Higuchi T; Taniguchi Y; Morinaga S; Horimoto T; Nakai M; Kadono Y; Nojima T; Tsuchiya H
Front Immunol; 2022; 13():980456. PubMed ID: 36238308
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
20. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]